These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38796181)

  • 1. Determinants of radiographic progression in early psoriatic arthritis: insights from a real-world cohort.
    Koc GH; Kok MR; do Rosario Y; Luime JJ; Tchetverikov I; Kasiem FR; Korswagen LA; Bijsterbosch J; Goekoop-Ruiterman YPM; van Oosterhout M; Baudoin P; Kok P; Dolhain RJEM; Vis M
    RMD Open; 2024 May; 10(2):. PubMed ID: 38796181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis.
    Geijer M; Lindqvist U; Husmark T; Alenius GM; Larsson PT; Teleman A; Theander E
    J Rheumatol; 2015 Nov; 42(11):2110-7. PubMed ID: 26472410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P; Husni ME; Kafka S; Chakravarty SD; Harrison DD; Lo KH; Xu S; Hsia EC; Kavanaugh A
    Arthritis Res Ther; 2020 Mar; 22(1):43. PubMed ID: 32143685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis.
    Mease P; van der Heijde D; Kirkham B; Schett G; Orbai AM; Ritchlin C; Merola JF; Pricop L; James DA; Zhu X; Ligozio G
    Arthritis Res Ther; 2022 Dec; 24(1):283. PubMed ID: 36578042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
    van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
    Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
    Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
    Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
    van der Heijde D; Gladman DD; FitzGerald O; Kavanaugh A; Graham D; Wang C; Fallon L
    J Rheumatol; 2019 Sep; 46(9):1089-1096. PubMed ID: 30824647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
    Mease PJ; Gottlieb AB; Ogdie A; McInnes IB; Chakravarty SD; Rampakakis E; Kollmeier A; Xu XL; Shawi M; Lavie F; Kishimoto M; Rahman P
    Clin Rheumatol; 2024 Jan; 43(1):241-249. PubMed ID: 37787903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study.
    Tillett W; Shaddick G; Jadon D; Robinson G; Korendowych E; McHugh N
    J Rheumatol; 2016 Feb; 43(2):367-70. PubMed ID: 26773116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
    van der Heijde D; Fleischmann R; Wollenhaupt J; Deodhar A; Kielar D; Woltering F; Stach C; Hoepken B; Arledge T; Mease PJ
    Ann Rheum Dis; 2014 Jan; 73(1):233-7. PubMed ID: 23942869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Swollen joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet.
    Simon P; Pfoehler C; Bergner R; Schreiber M; Pfreundschuh M; Assmann G
    Clin Exp Rheumatol; 2012; 30(1):45-50. PubMed ID: 22274638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).
    Wassenberg S; Rau R; Klopsch T; Plenske A; Jobst J; Klaus P; Meng T; Löschmann PA
    Rheumatol Ther; 2023 Feb; 10(1):117-133. PubMed ID: 36251174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.
    Kane D; Stafford L; Bresnihan B; FitzGerald O
    Rheumatology (Oxford); 2003 Dec; 42(12):1460-8. PubMed ID: 14523223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.
    Ritchlin CT; Coates LC; Mease PJ; van der Heijde D; Song J; Jiang Y; Shawi M; Kollmeier AP; Rahman P
    Trials; 2023 Jan; 24(1):22. PubMed ID: 36627711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.
    Jadon DR; Shaddick G; Tillett W; Korendowych E; Robinson G; Waldron N; Cavill C; McHugh NJ
    J Rheumatol; 2015 Jul; 42(7):1169-76. PubMed ID: 25979723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiological progression and predictive factors in psoriatic arthritis: insights from a decade-long retrospective cohort study.
    Ozdemir Isik O; Gokcen N; Temiz Karadag D; Yazici A; Cefle A
    Clin Rheumatol; 2024 Jan; 43(1):259-267. PubMed ID: 38044416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis.
    Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M;
    Arthritis Res Ther; 2019 Jan; 21(1):25. PubMed ID: 30651121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Gladman DD
    Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
    Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.